Jennifer August, PA
Medical · Mashpee, MANPI 1871628693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,528, more than ten times the $106 reported in 2021. Among medical clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$525
- Novo Nordisk$384
- Abbott$379
- Boehringer Ingelheim$228
- Lilly USA, LLC$215
- GSK$195
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,20199%
- Education$120%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $525 |
| Novo Nordisk | 8 | $384 |
| Abbott | 9 | $379 |
| Boehringer Ingelheim | 6 | $228 |
| Lilly USA, LLC | 10 | $215 |
| GSK | 9 | $195 |
| Xeris Pharmaceuticals, Inc. | 8 | $174 |
| E.r. Squibb & Sons, L.L.C. | 7 | $161 |
| Insulet Corporation | 1 | $150 |
| Fresenius Kabi USA, LLC | 5 | $127 |
| Medtronic | 6 | $124 |
| Tandem Diabetes Care, Inc. | 4 | $103 |
| UCB, Inc. | 5 | $98 |
| BETA Bionics, Inc. | 1 | $86 |
| Bayer | 3 | $56 |
| Dexcom, Inc. | 2 | $52 |
| AbbVie | 2 | $35 |
| Vertex | 1 | $30 |
| Sequel Med Tech, LLC | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Sanofi | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,233 in reported general payments places this provider in the 90th percentile of 421 medical providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 467 | $692,825 |
| TrulicityDulaglutide | 325 | $419,956 |
| JardianceEmpagliflozin | 359 | $377,345 |
| MounjaroTirzepatide | 176 | $211,517 |
| FarxigaDapagliflozin Propanediol | 156 | $143,393 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $97,160 |
| TradjentaLinagliptin | 95 | $83,449 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $73,358 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $73,297 |
| JanuviaSitagliptin Phosphate | 62 | $63,984 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $57,141 |
| RybelsusSemaglutide | 44 | $44,687 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $25,582 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 195 | $20,963 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $15,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $384 | $742,991529 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $215 | $631,473501 claims |
| Boehringer IngelheimJardiance, Tradjenta | $228 | $460,794454 claims |
| Sanofi-aventis U.S. LLCLantus | $25 | $3,32216 claims |
| AbbVieSynthroid | $35 | $1,83726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 421 medical providers in Massachusetts.
Other medical in Mashpee
- Eileen CheeverLeominster$389K
- Vidal PrimiterioLawrence$22K
- Michelle BaytarianJamaica Plain$17K
- Julia FioreAgawam$16K
- Jennifer LevesqueFall River$15K
- Ashley HoffmanWestfield$13K
- Theresa FukudaBoston$13K
- Christina MessingerPlymouth$11K
- Lauren CarraSpringfield$9K
- Raul AliceaSpringfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.